Experimental prostate cancer combo trial halted early
NCT ID NCT05733351
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a new immunotherapy drug called vudalimab (XmAb20717) alongside standard treatments for men with metastatic castration-sensitive prostate cancer. The study aimed to check safety and early signs of effectiveness. However, the trial was terminated early after enrolling only 4 participants, so no conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vudalimab (XmAb20717) plus standard of care (abiraterone, enzalutamide, or docetaxel)
What this could lead to
If successful, this could point toward a new combination therapy that helps control metastatic prostate cancer for longer.
What could go wrong
This was a very early, small Phase 1 trial that was terminated early with only 4 participants. It is too early to know if the combination is safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States